Use of LCAT to Reduce Cholesterol and Prevent Atherosclerosis
Posted Jun 15 2010 5:00pm
Description of Invention: Available for licensing and commercial development is a method of decreasing accumulation of cholesterol in arteries of humans by administering lecithin-cholesterol acyltransferase (LCAT). This method is useful for the therapeutic treatment of subjects at risk for developing atherosclerosis.
High plasma concentration of HDL cholesterol is associated with reduced risk of cardiovascular diseases (such as ischemic stroke and myocardial infarction). In contrast, low levels of HDL are associated with increased risk of atherosclerotic diseases. The plasma protein enzyme LCAT plays a critical role in the metabolism of HDL and it facilitates the removal of cholesterol from the body. Individuals with a mutation in the LCAT gene have low HDL plasma levels and exhibit an increased risk for atherosclerosis.
Therefore, upregulation of LCAT function has been proposed as an HDL-C increasing therapy, and may have atheroprotective effects. This invention provides for several methods of administering LCAT polypeptide to decrease cholesterol accumulation in arteries.
Development Status: Animal data available.
Inventors: Silvia Santamarina-fojo (NHLBI) Jeffrey M Hoeg (NHLBI) H. Bryan Brewer (NHLBI)
JM Hoeg et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA. 1996 Oct 15;93(21):11448-11453. [ PubMed abs ]
Licensing Status: Available for non-exclusive or exclusive licensing.
Portfolios: Internal Medicine Internal Medicine - Therapeutics In-vivo Data
For Additional Information Please Contact: Fatima Sayyid MHPM NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 21, Rockville, MD 20852 United States Email: Fatima.Sayyid@nih.hhs.gov Phone: 301-435-4521 Fax: 301-402-0220